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Adjuvant Carboplatin-based Chemotherapy in Resected
Stage IIIA-N2 Non-small Cell Lung Cancer
Wei Ou, MD,* Hai-bo Sun, MD,* Xiong Ye, MD,† Bin-bin Zhang, MD,‡ Hua Yang, MD,§
Qin Fang, MD,* Pan Li, MD,* and Si-yu Wang, MD*
Instruction: We determined whether adjuvant vinorelbine/pacli-
taxel plus carboplatin prolonged overall survival among patients
with completely resected stage IIIA-N2 non-small cell lung cancer
(NSCLC).
Methods: We randomly assigned patients with completely resected
stage IIIA-N2 NSCLC to a control group or to a treatment group
with vinorelbine/carboplatin or paclitaxel/carboplatin doublet adju-
vant chemotherapy. The primary endpoint was overall survival;
secondary endpoints were disease-free survival and the toxicity and
safety of the regimen.
Results: This trial was terminated before accumulation of the
planned numbers for registration because of the results of bigger
clinical trial. Finally, 150 patients underwent randomization to
vinorelbine/paclitaxel plus carboplatin (79 patients) or observation.
In the chemotherapy group, 38 patients received vinorelbine plus
carboplatin and 41 patients received paclitaxel plus carboplatin. In
both groups, the median age was 57 years, 73% were men, and 28%
had squamous carcinoma. Chemotherapy caused neutropenia in 82%
of the patients (including grade 3 and 4 neutropenia in 42%), and
there were no treatment-related deaths in this trial. After a median
follow-up of 29 months (range, 1–110 months), the overall survival
was significantly prolonged in the chemotherapy group, when com-
pared with the observation group (33 months 95% confidence
interval {CI}, 27.4–38.6 versus 24 months 95% CI, 15.8–32.2,
p  0.037), as was disease-free survival (32 months 95% CI,
21.3–42.7 versus 20 months (95% CI, 13.1–26.9), p  0.020). The
5-year overall survival rates were 31.1% and 19.1%, respectively.
Conclusions: Although with limitations, this clinical trial showed
that adjuvant vinorelbine/paclitaxel plus carboplatin has an accept-
able level of toxicity and prolongs disease-free and overall survival
among patients with completely resected stage IIIA-N2 NSCLC.
Key Words: Non-small cell lung cancer, Adjuvant chemotherapy,
Vinorelbine, Paclitaxel, Carboplatin.
(J Thorac Oncol. 2010;5: 1033–1041)
Lung cancer is the most frequent cancer worldwide.1 Non-small cell lung cancer (NSCLC) represents 80% of all
lung tumors, and in its early stages, it is treated surgically
with curative intent. However, 30 to 70% of patients under-
going resection develop recurrence and die of their disease.2
Managing locally advanced stage IIIA and IIIB NSCLC is
often fraught with difficulties. Based on a series of 5230
patients with NSCLC cared for between 1975 and 1988 at the
M. D. Anderson Cancer Center, as reported by Dr. Clifford
Mountain in the 1997 revision of the lung cancer staging
criteria, 30% of all patients have locally advanced disease
(stages IIIA and IIIB) at the time of initial presentation.
Indeed, this group forms the most therapeutically challenging
and controversial subset of patients with lung cancer.3 Mi-
crometastases at distant sites are present in nearly 80% of
patients with stage IIIA NSCLC.4 Molecular techniques have
demonstrated the early spread of tumor cells to the lymph
nodes, whereas the presence of malignant cells in the periph-
eral blood is probably the major cause of early death after
complete resection.5,6
For these reasons, combined treatment modalities are
preferred over surgery alone. Numerous trials of adjuvant
postoperative chemotherapy have been performed over the
past three decades. A meta-analysis by the Non-small Cell
Lung Cancer Collaborative Group in 1995 analyzed eight
cisplatin-based adjuvant chemotherapy trials and reported
a 13% decrease in the relative risk of death with chemo-
therapy and an absolute survival benefit of 3% at 3 years
and 5% at 5 years, but none of the differences were
statistically significant (hazard ratio HR  0.87, p 
0.08).7 These provocative results led to the development of
at least five randomized controlled trials evaluating the
efficacy of cisplatin-based chemotherapy8 –12; three of these
trials revealed an improvement in overall survival with adju-
vant cisplatin-based therapy.8–10 Based on these five trials,
the recent lung adjuvant cisplatin evaluation (LACE) meta-
analysis revealed a significant improvement in overall sur-
vival with a combination of cisplatin-based chemotherapy
and surgery when compared with surgery alone (HR  0.89;
95% confidence interval CI, 0.82–0.96; p  0.005). The
*Department of Thoracic Surgery, Cancer Center of Sun Yat-sen University,
Guangzhou; †Department of Thoracic Surgery, Guangdong Provincial
People’s Hospital, Guangzhou; ‡Department of Thoracic Surgery, Henan
Chest Hospital, Zhengzhou; and §Department of Breast Surgery, Guang-
dong Hospital of Traditional Chinese Medicine, Guangzhou, People’s
Republic of China.
Disclosure: The authors declare no conflicts of interest.
Address for correspondence: Si-yu Wang, MD, Department of Thoracic
Surgery, Cancer Center of SunYat-sen University, Guangzhou 510060,
People’s Republic of China. E-mail: wsysums@163.net
W.O. and H.-b.S. contributed equally to this work.
Copyright © 2010 by the International Association for the Study of Lung
Cancer
ISSN: 1556-0864/10/0507-1033
Journal of Thoracic Oncology • Volume 5, Number 7, July 2010 1033
5-year absolute benefit from chemotherapy was 5.4%.13
These trials and the meta-analysis have established the effi-
cacy of adjuvant cisplatin-based therapy.
There were also some phase III studies evaluating
neoadjuvant chemotherapy and surgery versus surgery alone
in stage III NSCLC in early 1990s. Rosell et al.14 randomized
60 patients(44 had N2 disease) with resectable NSCLC to
receive surgery alone or three cycles of mitomycin, ifosf-
amide, and cisplatin followed by surgery. Trial enrollment
was prematurely halted after 24 months, when an interim
analysis demonstrated significant median survival differences
between the two arms (26 months for neoadjuvant chemo-
therapy group versus 8 months for surgery alone p  0.001).
In a subsequent long-term follow-up analysis,15 overall me-
dian survival was 22 months for patients receiving neoadju-
vant chemotherapy (versus 10 months with surgery alone,
p 0.005). Roth et al.16 from M. D. Anderson Cancer Center
performed a similar study, and the enrollment was also halted
after 60 of the planned 130 patients were accrued given the
results of an interim analysis indicating a significant survival
benefit with induction therapy (p  0.018). Conclusive evi-
dence regarding neoadjuvant chemotherapy for patients with
N2 disease with the use of older chemotherapeutic regimens
is thus lacking.
When we initiated this study in 1999, there were no
prospective randomized phase III trials, which were confined
to adjuvant chemotherapy in stage IIIA-N2 NSCLC. In this
report, we describe the results of our clinical study, which
was conducted at the Cancer Center of Sun Yat-sen Univer-
sity. The aims of this study were to assess the effect of
adjuvant chemotherapy on overall survival, disease-free sur-
vival, and pattern of relapse, as well as the toxicity of
chemotherapy in the patients who had undergone surgery for
stage IIIA-N2 NSCLC. In this study, carboplatin/vinorelbine
and carboplatin/paclitaxel doublets were used in the adjuvant
protocol. The regimens were chosen because they have po-
tentially less toxicity and better tolerability than cisplatin
combinations.17
PATIENTS AND METHODS
Study Design and Treatment Plan
This trial was conducted in the Thoracic Department at
the Cancer Center of Sun Yat-sen University; the trial com-
menced in January 1999 and enrollment stopped before
accumulation of the planned numbers in December 2003. The
study was designed as a randomized, prospective, single-
center, two-armed study, with surgery alone in one arm
versus surgery plus adjuvant vinorelbine/carboplatin or pac-
litaxel/carboplatin doublets. We did not perform randomiza-
tion between these two regimens and the chemotherapy
regimen either vinorelbine/carboplatin or paclitaxel/carbopla-
tin was chosen based on the oncologists’ decision only. A
simple randomization was used. A coordinator assigned the
patients into two groups after thoracic surgery checked the
patients’ eligibility. The Ethics Committee and Clinical Trial
Review Committee at the Cancer Center of Sun Yat-sen
University approved this proposal, and informed consent was
obtained from all patients.
Adjuvant chemotherapy began within 28 days after
randomization, which was conducted 30 days after surgery,
and patients randomly received vinorelbine (25 mg/m2) ad-
ministered as a 10-minute infusion on days 1 and 8, or
paclitaxel (175 mg/m2) given as a 3-hour infusion on day 1
with carboplatin (AUC  5) administered in a 60-minute
infusion. After chemotherapy, the patients received prophy-
lactic granulocyte colony-stimulating factor 2 (G-CSF) sup-
portive therapy at each cycle on days 2, 3, and 4 for pacli-
taxel/carboplatin regimen and on days 9, 10, and 11 for
vinorelbine/carboplatin regimen. Adjuvant chemotherapy
was administered only if adequate hematologic recovery had
occurred (neutrophil count 1500/mm3 and platelet count
10,000/mm3). However, if recovery did not occur, treat-
ment was delayed for a week. When necessary, dose adjust-
ment was done at the discretion of a medical oncologist.
Chemotherapy doses were modified one dose level for grade
4 neutropenia 7 days or grade 3 nonhematologic toxicity
7 days. Toxicity was graded according to the World Health
Organization criteria.18 Patients were not permitted to receive
adjuvant radiotherapy after surgery.
Eligibility and Exclusion Criteria
Patients who had undergone microscopic complete re-
section of pathologically documented stage III-N2 NSCLC
by either lobectomy or pneumonectomy were eligible for this
study. The surgical procedures used for staging and treatment
of the mediastinal lymphatics included complete dissection of
the mediastinal lymph nodes at levels 4, 7, 8, 9, and 10 during
a right-sided thoracotomy and at levels 5, 6, 7, 8, 9, and 10
during a right-sided thoracotomy. We used revision of lung
cancer staging criteria3 as a guide to stage patients, and
according to this staging system, the mediastinal lymph nodes
were divided into three fields: (1) superior mediastinal lymph
nodes (highest mediastinal, upper paratracheal, prevascular,
retrotracheal, and lower paratracheal); (2) aortic field lymph
nodes (subaortic and paraaortic); and (3) inferior mediastinal
lymph nodes (subcarinal, paraesophageal, and pulmonary
ligament). The degree of mediastinal lymph nodes metastases
was divided into single-field metastases (F1) and multifield
metastases (F2 or F3).
The eligibility criteria included age 18 to 75 years,
good performance status of Eastern Cooperative Oncology
Group 1, no significant weight loss (5%), adequate bone
marrow reserves (white blood cell count, 4.0  109/L;
platelet count, 100  109/L; and hemoglobin 10 g/L),
adequate liver and renal function (aspartate aminotransferase
and alanine aminotransferase within the upper limits of nor-
mal; and a calculated creatinine clearance of 40 mL/min).
All the patients had the following staging investigations,
which included computed tomography (CT) scans of the
chest, abdomen, and magnetic resonance imaging or CT
scans of brain to exclude any systemic involvement. Bone
emission CT was obtained if clinically indicated. A medias-
tinoscopy was not performed. Exclusion criteria included
prior malignancy, coexisting serious nonstabilized disease, or
active uncontrolled infection. Patients who had received pre-
vious chemotherapy, immunotherapy, or thoracic irradiation
and patients who underwent sleeve or wedge resection of the
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tumor were not included in this study. Those patients with
potentially malignant mediastinal lymph nodes (1 cm in
diameter) more than one station or with bulky mediastinal
nodes before surgery were not eligible for this trial; all those
patients received neoadjuvant chemotherapy or definitive
chemoradiotherapy at our institute. Patients were checked the
eligibility and randomized 30 days after surgery.
Follow-Up
All patients were followed up after being discharged
from the hospital. Follow-up examinations were scheduled
monthly or bimonthly for the first 6 months, then every 3
months for the following 18 months, and semiannually there-
after. Patients were followed up until death or until the cutoff
date of the analysis, January 1, 2009. Routine follow-up
examinations included physical examination, chest x-ray
film, and ultrasound scan of the abdomen. CT scans of the
chest, abdomen, or magnetic resonance imaging of the brain
were also done when necessary. For some patients who did
not return to our hospital for follow-up evaluations, we
telephoned them to inquire about their status.
Statistical Analysis
The trial was designed to demonstrate an absolute
improvement in survival of 10%, from 20 to 30% (HR 
1.5), at 5 years with adjuvant chemotherapy according to the
data of previous study.3 Approximately, a total of 260 pa-
tients was required to provide the study with 80% power with
a 5% type I two-sided error rate, accounting for 196 events.
From the beginning of this trial, the rate of enrollment was
sluggish, and we abandoned this study in December 2003
after acquiring permission from the Cancer Center of Sun
Yat-sen University Clinical Trial Review Committee mainly
because of the results of the Randomized International Ad-
juvant Lung Cancer Trial presented in 2003 annual meeting
of American Society of Clinical Oncology.19 The results were
based on an analysis performed in January 2009, approxi-
mately 10 years after the initiation of this study. The median
duration of follow-up was 29 months (range, 1–110 months).
The primary endpoint of this study was overall sur-
vival, which was defined as the interval from randomization
to death from any cause or last observation. Secondary
endpoints were disease-free survival, defined as the interval
from the randomization to the detection of recurrence and
toxicity associated with chemotherapy. Data on patients who
were alive were censored on the date on which they were last
known to be alive. Data on patients without recurrent disease
were censored on the date of death or the last follow-up visit.
Survival and time to recurrence were estimated with the
use of the Kaplan-Meier method, the differences between
groups were computed with the log-rank test, and the differ-
ences between subgroups were evaluated by the2 test for
categorical variables.20,21 A p value 0.05 was considered to
indicate statistical significance; all resulting p values were
two tailed. SPSS, version16.0 (SPSS Inc., Chicago, IL) was
used for statistical analyses.
An overall comparison of the two groups was made,
and we also compared outcomes in subgroups defined ac-
cording to specific variables as follows: metastatic nodal
status (F1 or F2 and F3), histologic findings (squamous cell
carcinoma or other types), number of metastatic lymph nodes
(1–3, 4–10, or 10), and T stage (T1, T2, and T3). Multi-
variate analyses with the Cox proportional hazards model
were used to estimate the simultaneous effects of prognostic
factors on survival.22 Stepwise selection was used to ensure
more parsimonious models. The variables were the stratifi-
cation factors (nodal metastases status, histologic findings,
number of metastatic lymph nodes, and T stage).
We also analyzed the recurrence patterns. The recur-
rence pattern was classified into three categories (locore-
gional, distant metastases, and brain). Locoregional recur-
rence included tumor spread to the supraclavicular nodes,
mediastinal nodes, pleural effusion or seeding, bronchial
stump, and ipsilateral lung. Distant metastases were catego-
rized as metastasis to the contralateral lung, bone, liver,
adrenal, and other organs excluding brain. Simultaneous
locoregional and distant metastases was considered the dis-
tant metastases group. We designated brain metastases as a
special group.
RESULTS
Characteristics of the Patients
We enrolled 150 patients with pathologic stage IIIA-N2
NSCLC into this trial between January 1999 and December
2003. Seventy-one patients were randomly assigned to un-
dergo surgery only, and 79 patients underwent surgery and
adjuvant vinorelbine/paclitaxel plus carboplatin doublet che-
motherapy.
Of the latter 79 patients, 38 patients received vinorel-
bine plus carboplatin and 41 patients received paclitaxel plus
carboplatin. In both groups, the median age was 57 years,
73% were men and 28% had squamous carcinoma. Table 1
lists the characteristics of the patients. The two groups were
well matched with respect to the age, gender, T stage,
histology, and operative procedure. Follow-up ranged from 1
to 104 months (median, 35 months) in the chemotherapy
group and 1 to 110 months (median, 28 months) in the
observation group. Five (3%) patients were lost to follow-up
(two in the treatment group and three in the observation
group).
Treatment Administration and Toxicity of
Chemotherapy
Of the 79 patients enrolled and treated in the trial, 64
(81.0%) received four cycles of full-dose therapy in 12 weeks
and three (3.8%) delayed chemotherapy because of severe
toxicity. All patients received at least one cycle of therapy,
and no dose reduction happened in this study. Twelve
(15.2%) patients did not complete four cycles of therapy, of
which six patients received three cycles of therapy, four
patients received two cycles of therapy, and two patients
received one cycle therapy. The basis for discontinuing ther-
apy included patient refusal (n  5), severe adverse events
(n  3), and disease progression during chemotherapy (n 
4, Table 2). Most of the patients (81%) received adjuvant
chemotherapy within 14 days after randomization.
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The toxicity of chemotherapy is presented in Table 3.
The primary hematologic toxicity that occurred in this trial
was neutropenia, with 41.8% (n  33) of patients developing
grade 3 or 4 neutropenia. Approximately 30% (n  24) of
patients developed grade 3 neutropenia, and 11% (n  9)
of the patients experienced grade 4 neutropenia. The rate of
grade 3 or 4 anemia and thrombocytopenia was low (2.5%
and 0%, respectively). The most frequent nonhematologic
toxicity was alopecia, with 75.9% patients developing grade
2 alopecia. Fatigue occurred in 49.4% of the patients. Gas-
trointestinal toxicity was mild, although nausea occurred in
91.1% of the patients. The grade 3/4 toxicity happened in two
regimens was presented in Table 4, but we did not make a
comparison between them because of small sample size and
no randomization performed between the two regimens. Pro-
phylactic G-CSF supportive therapy and relatively lower dose
of carboplatin may be associated with low hematologic tox-
icity, especially neutropenia.
Disease-Free Survival and Overall Survival
Recurrence was documented in 108 (72%) patients (57
in the group assigned to chemotherapy and 51 in the obser-
vation group; 2  0.005, p  0.965). The interval from
randomization to recurrence varied from 1 to 91 months, and
the median value was 20 months. The initial recurrence sites
were analyzed and are presented in Table 5. Distant metas-
tases were identified in 71 patients (chemotherapy group, 35
and observation group, 36) and locoregional recurrence was
identified in 37 patients (chemotherapy group, 22 and obser-
vation group, 15). Only first site of recurrence were recorded
for patients who had recurrence at more than one site. The
most common site of distant recurrence was the brain, and a
total of 38 (25.3%) patients were identified to have brain
metastases (22 27.8% in the chemotherapy group and 16
22.5% in the observation group;2  0. 558, p  0.455).
The Kaplan-Meier estimates of disease-free survival
are shown in Figure 1. The 3- and 5-year disease-free survival
rates were 47.9% (standard error SE, 0.060) and 17.9% (SE,
0.050) in the chemotherapy group and 30.4% (SE, 0.063) and
14.7% (SE, 0.053) in the observation group, respectively. The
median time of disease-free survival in the chemotherapy and
observation groups was 32 (95% CI, 21.3–42.7) and 20
months (95% CI, 13.1–26.9), respectively (HR  1.560; 95%
CI, 1.064–2.287; p  0.020).
One hundred sixteen patients (56 in the observation
group and 60 in the chemotherapy group) had died when the
database was locked in January 2009. In observation group,
52 deaths were cancer related, and three patients died of other
reasons: two of chronic obstructive pulmonary disease and
one of acute myocardial infarction. In addition, one patient
died of unclear reason. In chemotherapy group, 57 deaths
were cancer related, and three patients died of other reasons:
one of acute pulmonary infarction, one of chronic hepatic
cirrhosis, and one patient died in an accident. Figure 2 shows
the Kaplan-Meier estimates of overall survival. The median
time of overall survival in the chemotherapy group was 33
months (95% CI, 27.4–38.6) and 24 months (95% CI, 15.8–
32.2) in the observation group (HR  1.466; 95% CI,
1.017–2.114; p  0.037). The 3- and 5-year overall survival
rates were 44.6% (SE, 0.057) and 31.1% (SE, 0.053) in the
chemotherapy group and 35.4% (SE, 0.057) and 19.1% (SE,
0.048) in the observation group, respectively. There was an
absolute survival advantage of 12.0% at 5 years with chemo-
therapy.
A multivariate analysis of prognostic factors in the Cox
proportional hazard model confirmed that only T stage
(HR  1.562; 95% CI, 1.146–2.128; p  0.007), adjuvant
chemotherapy (HR  1.505; 95% CI, 1.040–2.178; p 
TABLE 1. Characteristics of the Patients
Characteristics
Chemotherapy
Group (%)
Observation
Group (%) p
Number 79 71
Age (yr)
Median 54 59
Range 31–73 24–75 0.629
Sex
Male 56 (70.8) 54 (76.1)
Female 23 (29.2) 17 (23.9) 0.475
Histologic features
Squamous 18 (22.8) 24 (33.8)
Nonsquamous 61 (79.2) 47 (69.2) 0.133
T stage
T1 8 (10.1) 9 (12.7)
T2 55 (69.6) 37 (52.1)
T3 16 (20.3) 25 (35.2) 0.076
N stage
Metastatic no. of LN
1–3 48 (60.8) 47 (66.2)
4–10 30 (38.0) 23 (32.4)
10 1 (1.2) 1 (1.4) 0.775
Metastatic level of LN
F1 50 (63.3) 55 (77.5)
F2 26 (32.9) 14 (19.7)
F3 3 (3.8) 2 (2.8) 0.164
Extent of resection
Lobectomy 68 (86.1) 54 (76.1)
Pneumonectomy 11 (13.9) 17 (23.9) 0.116
F1, single field metastases; F2, double field metastases; F3, triple field metasteses;
LN, lymph node.
TABLE 2. Chemotherapy Compliance
Parameters
Vin/Car
(n  38)
Pac/Car
(n  41) Total (%)
Completed chemotherapy
within 12 wk
29 (76.3) 35 (85.4) 64 (81.0)
Did not complete
chemotherapy
7 (18.4) 5 (12.2) 12 (15.2)
Chemotherapy delayed 2 (5.3) 1 (2.4) 3 (3.8)
Reasons for treatment
discontinue
Patient refusal 3 (7.9) 2 (4.9) 5 (6.3)
Severe adverse events 2 (5.3) 1 (2.4) 3 (3.8)
Disease progression 2 (5.3) 2 (4.9) 4 (5.1)
Vin, vinorelbine; Car, carboplatin; Pac, paclitaxel.
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0.026), and the number of metastatic lymph nodes (HR 
1.604; 95% CI, 1.049–2.453; p  0.038) were significant
factors for the prediction of prognosis. Unexpectedly, nodal
metastases status (F1 or F2 andF3) was not a significant
factor (HR  0.965; 95% CI, 0.644–1.445; p  0.876) that
affected the prognosis of the patients. The results of multi-
variate analysis are shown in Table 6.
DISCUSSION
Although complete resection for patients with stage
IIIA NSCLC is technically feasible, the 5-year survival is
only 23% treated with surgery alone.3 Most of recurrences are
outside the field of surgical resection, accounting for the most
common cause of death after complete resection, suggesting
that systemic approaches are needed to improve the cure rate.
Indeed, there remain many controversies in the management
of stage IIIA-N2 NSCLC.23 When we initiated this study in
1999, there was no single randomized prospective study
designed to include only N2 disease and address adjuvant
chemotherapy benefit in this heterogeneous group.
Although this prospective, randomized trial was termi-
nated before accruing the planned sample size, it documents
the benefit of adjuvant vinorelbine/paclitaxel plus carboplatin
in completely resected, stage IIIA-N2 NSCLC. The median
time of disease-free survival of the chemotherapy and obser-
vation group was 32 months (95% CI, 21.3–42.7) and 20
months (95% CI, 13.1–26.9), respectively. Chemotherapy
significantly prolonged disease-free survival, when compared
with observation group (HR  1.560; 95% CI, 1.064–2.287;
p  0.020). The median time of overall survival in the
chemotherapy group was 33 months (95% CI, 27.4–38.6) and
24 months (95% CI, 15.8–32.2) in the observation group
(HR  1.466; 95% CI, 1.017–2.114; p  0.037). The overall
survival advantage at 5 years was 12.0%. Although our data
showed a positive outcome for adjuvant chemotherapy in
stage IIIA-N2 NSCLC, the results of previous large random-
TABLE 3. The Main Toxicity of Chemotherapy
Toxicity
Degree of Toxicity
0 (%) 1 (%) 2 (%) 3 (%) 4(%) Grade 3/4 (%)
Hematologic toxicity
Leukopenia 15 (19.0) 15 (19.0) 34 (43.0) 15 (19.0) 0 (0) 15 (19.0)
Neutropenia 14 (17.7) 10 (12.7) 22 (27.8) 24 (30.4) 9 (11.4) 33 (41.8)
Anaemia 19 (24.1) 46 (58.2) 12 (15.2) 2 (2.5) 0 (0) 2 (2.5)
Thrombocytopenia 70 (88.6) 2 (2.5) 7 (8.9) 0 (0) 0 (0) 0 (0)
Nonhematologic toxicity
Nausea 7 (8.9) 60 (75.9) 10 (12.7) 2 (2.5) 0 (0) 2 (2.5)
Vomiting 65 (82.3) 10 (12.7) 2 (2.5) 2 (2.5) 0 (0) 2 (2.5)
Diarrhea 67 (84.8) 2 (2.5) 10 (12.7) 0 (0) 0 (0) 0 (0)
Alopecia 10 (12.7) 9 (11.4) 60 (75.9) — —
Fatigue 40 (50.6) 39 (49.4) 0 (0) 0 (0) 0 (0) 0 (0)
Dental ulcer 75 (94.9) 4 (5.1) 0 (0) 0 (0) 0 (0) 0 (0)
Dehydration 77 (97.5) 0 (0) 2 (2.5) 0 (0) 0 (0) 0 (0)
TABLE 4. Main Toxicity Between the Two Regimens
Grade 3/4
Toxicity
Vin/Car
(n  38)
Pac/Car
(n  41) Total (%)
Leukopenia 8 (21.1) 7 (17.1) 15 (19.0)
Neutropenia 18 (47.4) 15 (36.6) 33 (41.8)
Anemia 1 (2.6) 1 (2.4) 3 (3.8)
Nausea 1 (2.6) 1 (2.4) 2 (6.3)
Vomiting 1 (2.6) 1 (2.4) 2 (3.8)
TABLE 5. Comparison of First Site Recurrence
Chemotherapy
(n  79)
Observation
(n  71)
Total
(n  150) p
Locoregional 22 (27.8%) 15 (21.1%) 37 (24.7%) 0.340
Distant, excluding
brain
13 (16.5%) 20 (28.2%) 33 (22%) 0.035
Brain 22 (27.8%) 16 (22.5%) 38 (25.3%) 0.455
FIGURE 1. Disease-free survival, all patients.
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ized trials about adjuvant chemotherapy in patients with
NSCLC are inconsistent.8–12
The Adjuvant Lung Project Italy trial was the first large
randomized controlled trial of platinum-based adjuvant che-
motherapy to be published.12 In this trial, 1209 patients were
randomized to receive 3 cycles of cisplatin with mitomycin/
vinderson/cisplatin (MVP) versus observation alone. Three
hundred ten patients enrolled in the trial had stage IIIA
disease, with 272 patients having N2 involvement. After a
median 64.5 month follow-up, no significant improvement in
overall survival (HR  0.96; 95% CI, 0.81–1.13; p  0.589)
or progression-free survival (HR  0.89; 95% CI, 0.76–1.03;
p  0.128) was observed.12 The reasons for the negative
outcome of this trial are not clear. The MVP regimen was
associated with poor compliance (69% of patients in the MVP
arm completed all chemotherapy doses, and 22% of patients
stopped treatment early because of toxicity).12 It may be that
patients received an inadequate total dose of chemotherapy.
Similarly, negative results were also presented in the much
smaller Big Lung Trial.11 In this trial, 381 patients (34% stage
IIIA) who underwent surgical resection were randomized to
adjuvant chemotherapy with three cycles involving one of
four cisplatin-based regimens versus no chemotherapy. Of
the chemotherapy group, only 60% of the patients received
all planned cycles. The study failed to identify a survival
benefit for patients receiving chemotherapy. The HR in favor
of no chemotherapy was 1.02 (95% CI, 0.77–1.35; p 
0.90).11 There was no evidence in subgroup analysis for
differential survival outcomes among different disease stages,
including the 99 patients with stage IIIA disease. The study
acknowledged that it was not statistically powered to detect a
survival benefit, even though the goal enrollment of 500
patients was met.11
In the International Adjuvant Lung Trial, 1867 patients
with complete resection of stage I through III NSCLC (479 in
stage III-N2 disease) were randomized to receive three or
four cycles of cisplatin-based adjuvant chemotherapy versus
observation.8 Overall, this trial confirmed an absolute 5-year
survival benefit of 4.1% for patients receiving adjuvant che-
motherapy (HR  0.86; 95% CI, 0.76–0.98; p  0.03). The
strongest benefit was seen in patients with stage III disease.8
In subsequent long-term follow-up at 7.5 years, the investi-
gators recently reported the updated results of this trial.
Results showed a beneficial effect of adjuvant chemotherapy
on overall survival (HR, 0.91; 95% CI, 0.81–1.02; p  0.10)
and on disease-free survival (HR, 0.88; 95% CI, 0.78–0.98;
p  0.02). However, there was a significant difference be-
tween the results of overall survival before and after 5 years
of follow-up (HR, 0.86; 95% CI, 0.76–0.97; p  0.01 versus
HR, 1.45; 95% CI, 1.02–2.07; p  0.04) with p  0.006 for
interaction. Similar results were observed for disease-free
survival. The analysis of nonlung cancer deaths for the whole
period showed an HR of 1.34 (95% CI, 0.99–1.81; p 0.06).
The investigators concluded that the difference in results
beyond 5 years of follow-up underscores the need for the
long-term follow-up of other adjuvant lung cancer trials and
for a better identification of patients deriving long-term ben-
efit from adjuvant chemotherapy.24 In our trial, follow-up
ranged from 1 to 104 months (median, 32 months) in the
chemotherapy group and 1 to 110 months (median, 24
months) in the observation group.
In another phase III randomized trial (Adjuvant Navel-
bine International Trialist Association), 840 patients with
resected stage IB to IIIA NSCLC from 101 centers in 14
countries were randomized to four cycles of adjuvant cispla-
tin in combination with vinorelbine or observation. In this
trial, 325 patients (39.1%) had stage IIIA disease, with 224
patients having N2 involvement. This trial confirmed a ben-
efit in survival with adjuvant chemotherapy with a median
survival of 65.7 months with chemotherapy compared with
43.7 months for controls (HR  0.80, 95% CI, 0.66–0.96;
p  0.017). The absolute 5-year survival benefit was 8.6%
with chemotherapy, with the survival benefit persisting at
8.4% at 7 years.9 Subgroup analysis according to lymph node
station involvement indicated a nonsignificant trend toward
increasing survival benefit in patients with more advanced
lymph node station involvement (5-year survival of N0 sta-
tus, 58% chemotherapy versus 61% control; N1 status, 52%
versus 36%; N2 status, 40% versus 19%, respectively).9 The
authors concluded that because of the low number of patients
in each subgroup, definitive conclusions could not be made
based on the results of this study alone.9
FIGURE 2. Overall survival, all patients.
TABLE 6. Multivariate Analysis of Overall Survival
Variable
(Unfavorable vs. Favorable)
Hazard Ratio
(95% CI) p
T Stage 1.562 (1.146–2.128) 0.007
Postoperative chem. 1.505 (1.040–2.178) 0.026
Metastatic number of LN 1.604 (1.049–2.453) 0.038
Histologic features 1.083 (0.879–1.334) 0.347
Metastatic level of LN 0.965 (0.644–1.445) 0.876
CI, confidence interval; LN, lymph node.
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Recently, the LACE Collaborative Group published the
results of a meta-analysis of five randomized trials of adju-
vant chemotherapy.13 Twenty-seven percent of the patients
had stage III disease. The overall HR of death was 0.89 (95%
CI, 0.82–0.96; p 0.005) at a median follow-up of 5.2 years.
The 5-year absolute benefit from chemotherapy was 5.4%.
The benefit was superior for stage II and III (HR, 0.83; 95%
CI, 0.73–0.95; and HR, 0.83; 95% CI, 0.72–0.94, respective-
ly).13 The meta-analysis did not report on survival separated
by nodal status. In 2009, LACE collaborative group25 re-
ported the subgroup analysis for the cisplatin-vinorelbine
regimen. The results showed that survival improvement at 5
years was 8.9% with cisplatin-vinorelbine versus observation
(HR 0.80, 95% CI, 0.70–0.91, p  0.001). Stage was a
significant predictor for benefits (test for trend, p  0.02;
benefit at 5 years: 14.7% stage III, 11.6% stage II, and
1.8% stage I). Similar benefits were seen for disease-free
survival (HR 0.75 0.67–0.85, p 0.001, stage III HR 0.62,
0.50–0.76, stage II HR 0.69, 0.57–0.83, and stage I HR
0.95, 0.76–1.19). With the exception of cisplatin-based clin-
ical trials, there were some other clinical trials involving the
orally available chemotherapeutic agent, uracil-tegafur
(UFT).26–29 The number of patients enrolled in these trials
was low, especially patients with stage III disease. The largest
meta-analysis of adjuvant chemotherapy incorporated up-
dated information involving 8147 patients enrolled in 30
randomized controlled trials.30 Cisplatin-based chemotherapy
without UFT was administered in 15 of the trials, whereas
seven trials administered UFT with cisplatin and eight trials
evaluated UFT alone. Seventeen percent of patients had stage
IIIA disease at the time of resection. The results of the
meta-analysis showed a highly significant HR (0.87) favoring
adjuvant chemotherapy (p  0.000001). An absolute benefit
from adjuvant chemotherapy at 5 years was 4% (60% 5-year
survival rate for controls versus 64% with chemotherapy).
Nevertheless, this meta-analysis was unable to identify a
clear indication of a difference in effect between different
chemotherapeutic regimens or between disease stage and
differences in survival benefit.30
In summary, there are no large randomized prospective
studies designed to include only N2 disease and address
adjuvant chemotherapy benefit in this heterogeneous group.
The data were derived from large studies and subset analyses.
The results of previous randomized prospectively studies
varied greatly, and the chemotherapy regimens used in these
studies were very different. Although the LACE meta-anal-
ysis noted superior survival with the combination of cisplatin
plus vinorelbine (HR  0.80, 95% CI, 0.70–0.90; p  0.04)
compared with other cisplatin-based combinations, the pa-
tients administered vinorelbine received a higher total dose of
cisplatin. The authors concluded that the relative survival
benefit may relate to the higher dose of cisplatin as opposed
to the vinorelbine itself.13
In our study, we used vinorelbine/paclitaxel plus car-
boplatin regimens, and this may have contributed to the high
compliance with chemotherapy and the positive outcomes.
Eighty-one percent of patients received four cycles of full-
dose chemotherapy within 12 weeks. However, the compli-
ance with chemotherapy in trials of cisplatin-based adjuvant
therapy range from 50 to 75% of the intended doses.8–12 The
toxicity of chemotherapy in our trial was mild, with 41% of
patients developed grade 3 or 4 neutropenia, of which 30% of
the patients developed grade 3 neutropenia and 11% of the
patients experienced grade 4 neutropenia. Data of the LACE
meta-analysis showed that the rate of overall grade 4 toxicity
was 32%, and the most frequent toxicity was neutropenia
(grade 3, 9% and grade 4, 28%).13
The compliance with chemotherapy in our trial was
similar to the CALGB 9633 trial.31 This trial, conducted by
the Cancer and Leukemia Group B, recruited 344 patients
with stage IB disease. Patients were randomized within 4 to
8 weeks after undergoing complete surgical resection to
observation only or to four cycles of chemotherapy with
paclitaxel (200 mg/m2) and carboplatin (AUC  6) admin-
istered on day 1 and 3 weeks. Preliminary chemotherapy
compliance data from the CALGB 9633 trial showed that
85% of the patients received four cycles of therapy and
55% received the four cycles at full dose.31 The most
common toxicity observed was grade 3 or 4 neutropenia in
36% of the patients.
The efficacy and toxicity of carboplatin and cisplatin in
advanced NSCLC has frequently been debated. The meta-
analysis of Hotta et al.32 revealed that when compared with
carboplatin in combination with third-generation regimens, a
cisplatin-based regimen in combination with a third-genera-
tion regimen had a statistically significant survival advantage
(HR  1.016; 95% CI, 1.005–1.218; p  0.039). Although
cisplatin-based therapy has better efficacy compared with
carboplatin-based therapy, low compliance with chemother-
apy due to toxicity may erode its advantage over the less
active carboplatin-based therapy. According to the results of
recent phase III trials8–10 and the results of the LACE meta-
analysis,13 cisplatin-based therapy should be considered the
standard therapy. However, many patients are not suitable
candidates for cisplatin-based therapy and may not tolerate
excessive toxicity. We believe that carboplatin-based che-
motherapy remains a good option for patients who cannot
tolerate cisplatin-based therapy, although at present carbo-
platin-based therapy should be considered investigational.
The issue of the better choice of platinum agents (cisplatin
versus carboplatin) in adjuvant chemotherapy of resected
NSCLC is worthy of more specifically designed prospec-
tive phase III trials.
In our study, the most frequent site of distant metasta-
ses was the brain, which was similar as the results of oth-
ers.33,34 Approximately 40% of patients with stage IIIA
NSCLC treated with surgical resection have been reported to
develop brain metastases.34,35 In our study, we found a lower
incidence of brain metastases (25.3% of patients developed
brain metastases 27.8% in the chemotherapy group and
22.5% in the observation group; p  0.455). Thus, chemo-
therapy could not reduce the risk of developing brain metas-
tases. Male subjects seemed to be at higher risk of developing
brain metastases. However, the low number of cases does not
allow further conclusions to be made. In one of our previous
studies, we built a prophylactic cranial irradiation (PCI)
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model to predict the risk of developing brain metastases in
patients with locally advanced NSCLC,36 and in one of our
present ongoing trials, we permitted patients at high risk for
brain metastases to undergo PCI after surgery to investigate
the role of PCI in locally advanced NSCLC. Thus, the role of
PCI needs to be carefully investigated considering the toxic-
ity of irradiation.
In previous studies, several factors, such as the number
of metastatic N2 stations, the T factor, skip N2, and adjuvant
chemotherapy had been reported as important prognostic
factors in patients with stage III-N2 NSCLC.37–41 On the
basis of a multivariate analysis of prognostic factors in the
Cox proportional hazard model, we confirmed that only
advanced T stage (HR  1.562; 95% CI, 1.146–2.128; p 
0.007), adjuvant chemotherapy (HR  1.505; 95% CI,
1.040–2.178; p  0.026), and the number of metastatic
lymph nodes (HR 1.604; 95% CI, 1.049–2.453; p 0.038)
were significant factors for prediction of a poor prognosis
(Table 6). In our study, we unexpectedly found that the level
of metastatic N2 stations had no significant affect on prog-
nosis (HR  0.965; 95% CI, 0.644–1.445; p  0.876); this
contrasts with the results reported by others.37,41 Vansteenkiste
et al.41 reported that the 5-year survival for patients with single
station N2 was 29.6% versus 20.8% for those with multiple
station N2 (p  0.008). In our study, we did not compare
survival for patients with single-station N2 versus multiple-
station N2 but compared single-field versus multiple-field and
most of the patients are in the F1 group and the number of
patients in the F2 and F3 groups is 40 and 5, respectively. This
may have accounted to the negative results of our study.
Overall, this study indicates that adjuvant treatment
with vinorelbine/paclitaxel plus carboplatin can be safely
administered with limited toxicity with G-CSF supportive
treatment. The regimens are beneficial in patients with com-
pleted resected stage IIIA-N2 NSCLC. Clearly, however, N2
is a heterogeneous disease that can range from minimal N2
disease (microscopically found after surgical resection) to
bulky disease (with multistation disease in the mediastinum).
Patients who were enrolled in our study were those who were
suitable for surgery (tumors which could be completely
resected), and this may contribute to more favorable survival
times than the results reported by another study.37There are
still many problems which need to be solved in the treatment
of this group of patients. Our current staging system does not
discriminate among N2 disease patients, and hence, this
crucial factor must be carefully evaluated when we analyze a
clinical trial results before prescribing a therapeutic approach.
We should study this particular stage using strict inclusion
criteria and avoid other confounding factors that may allow
us to get a conclusive answer. Perhaps, gene expression
profiling in lung cancer will provide new information on the
behavior of this disease, and perhaps, a molecular rather that
an anatomic classification may offer better patient stratifica-
tion and selection in the future.
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